human trial of Arginyl-fructose(Ginsenose) on decrease of body fat

12 weeks, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Arginyl-fructose(Ginsenose) on decrease of body fat

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0006674

Enrollment

Registered

2021-10-18

Start date

2021-03-25

Completion date

Unknown

Last updated

2023-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : • Arginyl-fructose(Ginsenose) group: 3times a day, 2 capsules at a time, oral intakes after breakfast /lunch/dinner, for 12 weeks(1.5 g/day, 1.5 g/day for Arginyl-fructose(Ginseno

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 25 kg/m²=BMI(Body mass index)=34.9 kg/m², PBF(Percent body fat) is over 25% as male, over 30% as female. 2) Participants who have fully understand the information provided about the study voluntarily decided to participate and agree to comply with precautions

Exclusion criteria

Exclusion criteria: 1) Participants who have a change of weight over 10% within 3 months prior to the screening examination 2) Participants who have an obesity surgery within 1 year 3) Participants with a history of medicine abuse 4) Participants who have participated in other clinical trials within 3 months prior to the screening examination

Design outcomes

Primary

Measure	Time frame
Body fat mass	—

Secondary

Measure	Time frame
Fat free mass;Anthropometric index;Lipid metabolism index;Obesity hormone index	—

Countries

Korea, Republic of

Contacts

Public Contactsoo jung Park

Woosuk University Korean Medicine Medical Center

taorgi@hanmail.net+82-63-220-8676

Outcome results